Developing new cancer treatment tools, using imaging techniques such as PET-CT and MRI, and new radiopharmaceuticals for next-generation personalized therapies (“Theranostics”) to target cancer first at the “diagnosis” phase and then at the “therapy” phase, using the same biological targets (“see to treat”).
DEA Hearing in 2024: Discussing the Fate of Two Psychedelics
The TDR Three Takeaways for DEA Hearings on psychedelics: The upcoming DEA hearing on June 10, 2024, will determine the classification of two hallucinogens, potentially
April 16, 2024